Introduction {#sec1}
============

Lung cancer is the most frequently diagnosed cancer in both men and women (14.5% and 8.4% of all diagnosed cases, respectively) and represents the leading cause of death in terms of mortality rate \[[@B1]\]. It is divided into two types that include small-cell lung carcinoma (15% of all cases) and non-small-cell lung carcinoma (NSCLC, 85%) \[[@B2]\]. Classic approaches such as surgery, adjuvant therapy, chemotherapy, and radiotherapy have been commonly used for treatment; however, customized therapy targeting appropriate oncogenes and immunotherapy have both been recently introduced. These novel strategies are considered as breakthrough treatments for improving the survival of NSCLC patients \[[@B3]\].

Axl, also known as Ark, Tyro7, or Ufo, is a receptor tyrosine kinase (RTK) that belongs to the TAM (Tyro3, Axl, MerTK) subfamily of RTKs \[[@B8],[@B9]\]. Previous studies have demonstrated that Axl is overexpressed in a broad range of cancers and can transduce multiple signals that regulate cell growth, survival, proliferation, invasion, migration, angiogenesis \[[@B10]\], and apoptosis \[[@B11],[@B12]\]. Axl is also reportedly correlated with highly aggressive cancers \[[@B13]\], epithelial-to-mesenchymal transition \[[@B16],[@B17]\], and chemoresistance \[[@B17]\]. This protein is a practical therapeutic target for successful cancer treatment, and small molecules that inhibit Axl have been exploited. BGB324 (R248) is a selective Axl inhibitor and the first candidate to be tested in phase I clinical trials for treatment of acute myeloid leukemia or NSCLC \[[@B20],[@B21]\]. BGB324-mediated Axl inhibition has been demonstrated to suppress the growth and metastasis of cancer cells and to induce apoptosis \[[@B21]\]. In addition to BGB324, a number of other inhibitors that function to suppress Axl expression and activation through different molecular mechanisms are under development \[[@B22]\].

Bufalin is one of the main active components of toad venom, which is a type of traditional Chinese medicine referred to as "Chan Su" or "Senso" \[[@B23]\]. Previous reports have demonstrated the anti-cancer effects of bufalin in the context of various types of cancers such as glioma \[[@B24]\], osteosarcoma \[[@B25]\], and breast \[[@B26]\], colorectal \[[@B27]\], ovarian \[[@B28]\], lung \[[@B29]\], pancreatic \[[@B30]\], gastric \[[@B31]\], and tongue cancer \[[@B32]\]. Bufalin is known to inhibit cell proliferation \[[@B24],[@B28]\] and metastasis \[[@B31]\], induce apoptosis \[[@B32]\], and reverse acquired drug resistance \[[@B33],[@B34]\]. Although the molecular mechanisms that underlie the anti-cancer activity of bufalin have been studied widely, bufalin's ability to affect Axl expression and the outcome in response to bufalin treatment in this context remain unexplored.

In the present study, we demonstrated that bufalin inhibits cell proliferation and induces apoptosis in NSCLC cells, and these phenomena were found to be associated with the down-regulation of Axl expression. The findings suggest that Axl may act as a substantial therapeutic target of bufalin, contributing to the anti-cancer effects of this therapeutic agent.

Materials and methods {#sec2}
=====================

Reagents and antibodies {#sec2-1}
-----------------------

Bufalin was obtained from Sigma-Aldrich (St. Louis, MO, U.S.A.). A549 and H460 cells were purchased from the American Type Culture Collection (Manassas, VA, U.S.A.). Primers for Axl and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were synthesized by the domestic company, Bioneer Corp. (Daejeon, Korea). TRI reagent was obtained from Solgent Co., Ltd. (Daejeon, Korea). AmpliTaq DNA polymerase was obtained from Roche Diagnostics Corp. (Indianapolis, IN, U.S.A.). G418 was from Gibco BRL (Gaithersburg, MD, U.S.A.). Lipofectamine 2000 and mammalian expression vector, pcDNA3, were obtained from Invitrogen (Carlsbad, CA, U.S.A.). The plasmid, pGL3-basic vector, and the Dual-Glo luciferase assay kit were purchased from Promega Corp (Madison, WI, U.S.A.). Pre-validated Axl-targeting siRNA and control siRNA were purchased from Bioneer Corp. For Western blot analysis, specific antibodies against Axl, GAPDH, and secondary antibodies were obtained from Santa Cruz Biotechnology (Dallas, TX, U.S.A.).

Cell culture {#sec2-2}
------------

The A549 and H460 cells were grown in Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco BRL) containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, 10 U/ml penicillin, and 10 g/ml streptomycin at 37°C in 5% CO~2~ in a water-saturated atmosphere.

Promoter activity measurement {#sec2-3}
-----------------------------

The promoter reporter plasmid, pGL3-Axl, containing the *Axl* promoter region ranging from −556 to +7 bp of the transcriptional start site was prepared. Polymerase chain reaction (PCR) was carried out with 2 µl of genomic DNA and 1 µl of each primers (sense; 5′-GAAGGTACCAATGAAGGGCCAAGGAGGC-3′ and anti-sense; 5′-TTGGATCCGCACCGCCACGCCATGGGTG-3′). PCR conditions were 1 cycle of 3 min at 94°C, then 30 cycles of 30 s at 94°C, 30 s at 65°C, and 1 cycle of 5 min at 72°C. PCR-amplified DNA fragment was subcloned into the pGL3-basic vector, the promoterless luciferase plasmid. The constructed promoter--reporter plasmid was co-transfected into cells (3 × 10^5^ cells in a 60-mm dish) with renilla luciferase vectors, pRL-SV40, as an internal control. Luciferase activity was measured using a Dual-Glo luciferase assay system. According to the manufacturer's instruction (Promega Corp, Madison, WI), luciferase assays were performed. Briefly, cell lysates were prepared from control cells as well as bufalin (20, 40 and 80 nM)-treated cells for 4 or 8 h using Passive Lysis Buffer. A 20 μl of cell lysates were mixed with 100 µl of firefly luciferase reagent (Luciferase Assay Reagent II) and then firefly luciferase activity (*Axl* promoter activity) was immediately measured. Next, 100 µl of Stop & Glo™ reagent was added to the reaction mixture and then *Renilla* luciferase activity was also measured. The ratio of firefly to Renilla luciferase activity was calculated.

Western blot analysis {#sec2-4}
---------------------

Total cell lysates were prepared from cells treated with the indicated concentrations (0, 20, 40 and 80 nM) of bufalin using lysis buffer \[1% Triton X-100, 50 mM Tris (pH 8.0), 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM Na~3~VO~4~, and protease inhibitor cocktail. Untreated cells were used as controls. Protein concentrations were determined using Bio-Rad protein assays. Proteins from the cell lysates (20--40 μg) were separated by 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and electrotransferred onto nitrocellulose membranes. The membranes were blocked for 30 min at room temperature in Tris-buffered saline with 0.05% Tween-20 (TTBS) containing 5% non-fat dry milk, and then incubated with TTBS containing a primary antibody for 4 h at room temperature. After three times of 10-min washes in TTBS, the membranes were incubated with peroxidase-conjugated secondary antibody for 1 h. Following three additional 10-min washes with TTBS, the protein bands of interest were visualized using an enhanced chemiluminescence detection system (Amersham™ ECL™ Prime Western Blotting Detection Reagent; GE Healthcare, Piscataway, NJ, U.S.A.). Density of each protein level was measured by LAS-3000 Fujifilm Image Reader and Multi-Gauge 3.0 software and Axl protein level was normalized with that of GAPDH.

Reverse transcription PCR (RT-PCR) {#sec2-5}
----------------------------------

Cells (2 × 10^5^) were seeded in a 60-mm culture dish and grown overnight and then treated with the indicated concentrations (0, 20, 40, 80 nM) of bufalin for 8 h. Total RNA was extracted using TRI reagent and subjected to cDNA synthesis and PCR. The specific primers were as follows: Axl sense, 5′-AACCTTCAACTCC TGCCTTCTCG-3′ and antisense, 5′-CAGCTTCTCCTTCAGC TCTTCAC-3′; GAPDH sense, 5′-GGAGCCAAAAGGGTCAT CAT-3′ and antisense, 5′-GTGATGGCATGGACTGTGGT-3′.

Cell viability measurement {#sec2-6}
--------------------------

Cell viability was measured using Cell Counting Kit-8 assay kit (Dojindo Laboratories, Kumamoto, Japan). Cells (1 × 10^3^ cells/well) were seeded in 96-well plates and grown overnight and then treated with the indicated concentrations (0, 20, 40, or 80 nM) of bufalin for 24 or 48 h. At the end of treatment, 10 μl of CCK-8 solution was added and further incubated for 4 h. The absorbance at 570 nm was measured using a microplate reader (Model 680 microplate reader, Bio-Rad Laboratories). Values are normalized to that of untreated control cells to determine the % of viability and expressed as a percentage of the viable cells with respect to control cells.

Colony formation assay {#sec2-7}
----------------------

Cells were seeded into 24-well plates (1--2 × 10^3^ cells/well) and treated with the indicated concentrations (0, 20, 40, and 80 nM) of bufalin for 24 h and then washed with PBS to remove bufalin. Thereafter, cells were cultured for the next 7 to 10 days to form colonies. Colonies were stained with Crystal Violet (in 60% methanol; Junsei Chemical Co., Ltd., Tokyo, Japan) and images were acquired using the RAS-3000 Image Analysis System (FujiFilm, Tokyo, Japan). To quantify the numbers of colonies, Crystal Violet dyes were extracted from colonies using 10% acetic acid and the optical density of the resolved Crystal Violet dye was measured at 570 nm.

Axl overexpression {#sec2-8}
------------------

To ectopically express Axl, the recombinant, pcDNA3-Axl, was constructed by cloning the Axl cDNA into the *Eco*RI and *Bam*HI sites of the pcDNA3 vector and 2 μg of purified plasmids were transfected into the A549 or A549/Cis cells (3 × 10^5^ cells in a 100-mm dish) using Lipofectamine 2000 (Invitrogen). To establish stable cell lines, which constitutively express Axl, the transfected cells were cultured in the presence of 400 μg/ml of G418. The RPMI 1640 medium containing G418 was refreshed every 3 days. After 3 to 4 weeks, the Axl-expressing cells were enriched and the Axl expression in these cells was analyzed by Western blot analysis.

Small interfering RNA (siRNA) transfection {#sec2-9}
------------------------------------------

RNA interference-mediated gene silencing was performed to reduce Axl protein level. Cells (5 × 10^5^) were seeded in 60-mm culture dishes, grown overnight and then transfected with 100 nM siRNA targeting Axl (sense, 5′-AAGAUUUGGAGAdACACACUGA-3′ and antisense, 5′-UCAGUGUGUUCUCCAAAUCUU-3′), or control siRNA. The cells were harvested at 24 or 36 h after transfection and used to evaluate protein expression and cell proliferation, respectively.

Detection of apoptosis {#sec2-10}
----------------------

Fluorescence-activated cell sorting (FACS) analysis was performed to detect apoptotic cells. Cells (3 × 10^5^ cells in a 60-mm dish) were seeded, grown overnight, and then treated with 40 nM bufalin for 24 h. The harvested cells were washed once with ice-cold PBS and re-suspended in 100 μl of 1× binding buffer (HEPES buffered saline solution supplemented with 2.5 mM CaCl~2~) and then incubated with 2  µg/ml of Annexin V-fluorescein isothiocyanate (FITC) and 2.5 μg/ml of propidium iodide (PI) for 30 min at room temperature in the dark. Next, 900 µl of 1× binding buffer was added to the mixture and subjected to flow cytometry using a Becton-Dickinson FACS Caliber and analyzed by Cell Quest software (Becton-Dickinson, San Jose, CA, U.S.A.).

Statistical analysis {#sec2-11}
--------------------

Data were expressed as the means ± SD of triplicate samples or at least three independent experiments. To determine statistical significance, the Student's *t*-test was used with a *P*-value threshold of \<0.05.

Results {#sec3}
=======

Bufalin inhibits the proliferation of NSCLC cells and induces apoptosis {#sec3-1}
-----------------------------------------------------------------------

We first examined the anti-proliferative effect of bufalin in the NSCLC cell lines A549 and H460. Cells were treated with 20, 40, or 80 nM concentration of bufalin for 24 or 48 h. As shown in [Figure 1](#F1){ref-type="fig"}A,B, cell viability was reduced in response to bufalin treatment in a time- and dose-dependent manner. The IC~50~ values of bufalin after 24 h in A549 and H460 cells were 28.16 and 38.70 nM, respectively.

![Bufalin inhibits cell proliferation and clonogenic activity and induces apoptosis\
(**A** and **B**) Cells were treated with 20, 40, or 80 nM bufalin for 24 or 48 h, and the viability of cells was measured using CCK-8 (\*\*\**P*\<0.001 vs untreated group). (**C** and **D**) Cells (2 × 10^3^ cells/well) were exposed to 20, 40, or 80 nM bufalin for 24 h, washed with PBS, and then allowed to grow for the next 7 to 10 days. The colonies were visualized by Crystal Violet staining (*P*\<0.001 (H460), ^\#\#\#^*P*\<0.001 (A549), vs untreated group). (**E**) Cells (3 × 10^5^ cells/ 60 mm dish) were exposed to 20, 40, or 80 nM bufalin for 24 h. The levels of PARP and γ-H2AX protein were determined by Western blot analysis.](bsr-40-bsr20193959-g1){#F1}

The inhibitory effect of bufalin on cell proliferation was further confirmed using colony formation assays. The clonogenic activity of cells treated with bufalin was decreased in proportion to the concentration of bufalin ([Figure 1](#F1){ref-type="fig"}C,D). Of note, both A549 and H460 cells treated with 80 nM of bufalin were observed to be unable to form colonies.

Next, we assessed the effect of bufalin on apoptosis by examining apoptotic changes such as poly (ADP-ribose) polymerase (PARP) cleavage and the induction of γ-H2AX (the phosphorylation of H2AX). Western blot analyses revealed that the levels of PARP were decreased and that those of cleaved PARP were increased in response to bufalin. Moreover, a dose-dependent induction of γ-H2AX was also observed in both A549 and H460 cells that were treated with the indicated concentrations of bufalin ([Figure 1](#F1){ref-type="fig"}E). Taken together, these results indicate that the anti-cancer effects of bufalin are a result of the inhibition of cell proliferation and the induction of apoptosis.

Bufalin suppresses Axl expression at the transcriptional level {#sec3-2}
--------------------------------------------------------------

As Axl is known to play critical roles in cell growth, proliferation, and survival, we investigated the effect of bufalin on Axl expression \[[@B35]\]. Western blot analyses revealed that bufalin treatment resulted in a dose-dependent decrease in the protein level of Axl in both A549 and H460 cells ([Figure 2](#F2){ref-type="fig"}A). Notably, Axl protein expression was almost undetectable in H460 cells that were treated with 80 nM of bufalin.

![Bufalin reduces Axl protein level and suppresses promoter activity\
(**A**) Cells (3 × 10^5^ cells/ 60 mm dish) were treated with 20, 40, or 80 nM bufalin for 24 h. Axl protein levels were determined by Western blot analysis. (**B**) For RT-PCR, total RNAs extracted from the cells treated with the indicated concentrations of bufalin for 8 h were used to measure Axl mRNA levels. (**C**) To examine the effect of bufalin on Axl promoter activity, H460/pGL3-Axl cells (3 × 10^4^ cells) were incubated with 20, 40, or 80 nM bufalin for 4 or 8 h, and the luciferase activities were then measured (\*\**P*\<0.01, \*\*\**P*\<0.001 (4 h), ^\#\#\#^*P* \< 0.001 (8 h), vs untreated group). (**D**) H460/pGL3-Axl cells were also treated with 40 nM bufalin for 0.5, 1, 2, 4, or 8 h, and then the luciferase activities were measured (\**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001, vs untreated group).](bsr-40-bsr20193959-g2){#F2}

The inhibition of Axl expression by bufalin treatment was also demonstrated using RT-PCR. Consistent with the results of Western blot, the mRNA levels of Axl in A549 and H460 cells were significantly decreased by bufalin treatment ([Figure 2](#F2){ref-type="fig"}B). Additionally, the *Axl* promoter activity was assessed to further illustrate the effect of bufalin on *Axl* gene expression. Cells harboring *Axl* promoter-luciferase reporter plasmids were exposed to bufalin at the indicated concentrations for 4 or 8 h. The cells were also treated with 40 nM of bufalin for the indicated time periods. As shown in [Figure 2](#F2){ref-type="fig"}C,D, bufalin treatment decreased luciferase activity in a dose- and time-dependent manner, indicating that bufalin suppressed the promoter activity of the *Axl* gene. Taken together, these results demonstrated that Axl expression was down-regulated by bufalin at the transcriptional level.

The anti-proliferative effect of bufalin is attenuated or augmented in accordance with the protein level of Axl {#sec3-3}
---------------------------------------------------------------------------------------------------------------

We subsequently assessed if the inhibitory effect of bufalin on cell proliferation is related to the down-regulation of Axl expression. Axl-overexpressing cells (H460/pcDNA3-Axl)) were prepared via the transfection of recombinant plasmids encoding the *Axl* gene and then treated with 40 nM of bufalin (a median of the concentration range used in cell viability test for 24 h. Western blot analyses demonstrated that the protein level of Axl was higher in H460/pcDNA3-Axl cells than that in control H460/pcDNA3 cells that were transfected with the empty vectors ([Figure 3](#F3){ref-type="fig"}A). As expected, even after 40 nM bufalin treatment, H460/pcDNA3-Axl cells possessed a higher protein level of Axl compared with that in H460/pcDNA3 cells. The proliferation of Axl-overexpressing cells was less affected by bufalin than that of control cells ([Figure 3](#F3){ref-type="fig"}B). Additionally, Axl-overexpressing cells formed more colonies than did the control cells, although the overall clonogenic activity was reduced in proportion to the concentration of bufalin ([Figure 3](#F3){ref-type="fig"}C,D). These results indicated that the anti-proliferative effect of bufalin is closely related to the protein level of Axl and can be attenuated by Axl overexpression, as demonstrated in H460/pcDNA3-Axl cells.

![The inhibitory effects of bufalin on cell proliferation, colony formation, and induction of apoptosis are attenuated by Axl overexpression\
(**A**) H460/pcDNA3 or H460/pcDNA3-Axl cells (3 × 10^5^ cells/ 60-mm dish) were exposed to 20, 40, or 80 nM bufalin for 24 h, and Western blot analysis was conducted to determine Axl protein levels. (**B**) Cells (2 × 10^3^ cells/ 96 well) were treated with the indicated concentrations of bufalin for 24 h, and cell viability were measured using CCK-8. (\*\*\**P*\<0.001 (H460/pcDNA3), ^\#\#\#^*P*\<0.001 (H460/pcDNA3-Axl), vs untreated group, \**P*\<0.05, \*\*\**P*\<0.0001, H460/pcDNA3 vs H460/pcDNA3-Axl). (**C**) Cells (2 × 10^3^ cells/24 well) were treated with 20, 40, or 80 nM bufalin for 24 h, washed with PBS, and then allowed to grow for the next 7 to 10 days. The colonies were visualized by Crystal Violet staining. (**D**) For quantification of colony formation assay, colonies were destained and the absorbance at 570 nm was then measured. (\*\*\**P*\<0.001, vs untreated group). (**E**) To detect apoptotic cells, cells were treated with 40 nM bufalin for 24 h, and the percentages of Annexin V and/or PI-stained cells were calculated.](bsr-40-bsr20193959-g3){#F3}

As Axl inhibition has been established to be linked to the induction of apoptosis \[[@B11],[@B12],[@B21]\], bufalin-induced apoptosis was further evaluated in both control and Axl-overexpressing cells via flow cytometry. As shown in [Figure 3](#F3){ref-type="fig"}E, the percentage of early (Annexin V-positive and PI-negative, Annexin V^+^/PI^−^) and late apoptotic cells (positive for both Annexin V and PI, Annexin V^+^/PI^+^) was found to be increased from 0.41% and 7.8% in untreated control cells to 2.8% and 19.5% in bufalin-treated cells, respectively. However, in Axl-overexpressing cells, each population of early and late apoptotic cells increased from 0.1% and 5.9% in untreated cells to 0.5% and 9.5% in cells exposed to 40 nM bufalin, respectively. These results indicate that there is an inverse correlation between the protein level of Axl and the induction of apoptosis by bufalin in NSCLC cells.

We then examined the effect of an *Axl*-specific siRNA (siAxl) on the anti-proliferative activity of bufalin. As shown in [Figure 4](#F4){ref-type="fig"}A, the protein level of Axl was decreased in H460/siAxl cells and was synergistically reduced by bufalin treatment. Consistent with the results of Western blot assays, inhibition of proliferation by bufalin was promoted in H460/siAxl cells to a higher degree than that in H460 cells transfected with control siRNA ([Figure 4](#F4){ref-type="fig"}B). The clonogenicity of H460/siAxl cells exposed to bufalin was additionally decreased compared to that of H460/siCtrl cells ([Figure 4](#F4){ref-type="fig"}C,D). Taken together, these results indicate that the protein level of Axl is proportional to the degree of cell proliferation, suggesting that Axl is a novel target of bufalin in interfering with the proliferation and clonogenic activity of NSCLC cells.

![Knockdown of Axl expression augments the inhibitory effect of bufalin on cell proliferation and colony formation\
Cells (3 × 10^5^ cells/dish) transfected with control siRNA (H460/siCtrl)) or Axl-specific siRNA (H460/siAxl) were incubated with 40 nM bufalin for 24 to 36 h and then harvested. (**A**) The protein levels of Axl were determined by Western blot analysis. (**B**) Cells (2 × 10^3^ cells/96 well) were treated with 40 nM bufalin for 24 h, and then the viability of cells was measured using CCK-8. (\*\*\*\**P*\<0.0001, vs untreated group). (**C** and **D**) Cells (2 × 10^3^ cells/24 well) were treated with 40 nM bufalin for 24 h, washed with PBS, and then allowed to grow for the next 7 to 10 days. For quantification, colonies were destained, and then the absorbance at 570 nm was measured (\*\*\**P*\<0.001 (siCtrl),^\#\#\#^*P*\<0.001(siAxl), vs untreated cells).](bsr-40-bsr20193959-g4){#F4}

Discussion {#sec4}
==========

*Axl*, a proto-oncogene, was originally isolated from chronic myelogenous leukemia \[[@B8]\] and has been reported to be critical for survival, metastasis, angiogenesis, epithelial-to-mesenchymal transition, and drug resistance in many cancer cells, including NSCLC \[[@B5],[@B10],[@B16],[@B18]\]. Accumulating evidence has demonstrated that interference with Axl expression and/or its activity results in inhibition of cell proliferation \[[@B36],[@B37]\], angiogenesis \[[@B38]\], migration, and invasion in cancer cells \[[@B39],[@B40]\], and results in a decrease in chemoresistance \[[@B41]\] and an increase in chemosensitivity \[[@B12],[@B41]\] and the induction of apoptosis \[[@B11],[@B12],[@B20],[@B21]\] in various cancer types. To date, Axl-targeting approaches, including small molecule kinase inhibitors \[[@B21],[@B22]\], monoclonal antibodies \[[@B42]\], and decoy receptors \[[@B45]\], have been evaluated as potent anti-cancer therapies, and some of these approaches are currently under clinical development. Therefore, the importance of Axl as an anti-cancer target continues to receive more attention.

Bufalin is an active bufadienolide extracted from the skin and parotid venom glands of toads \[[@B46]\]. It has been reported to exhibit remarkable anti-cancer activity against a number of cancers such as gastric cancer \[[@B31]\], glioma \[[@B14]\], colorectal cancer \[[@B27]\], esophageal carcinoma \[[@B47],[@B48]\], tongue cancer \[[@B32]\], osteocarcinoma \[[@B25]\], prostate cancer \[[@B49]\], and lung cancer \[[@B29]\]. In agreement with previous studies, the inhibitory effect of bufalin on cell proliferation was demonstrated in the NSCLC cell lines A549 and H460 ([Figure 1](#F1){ref-type="fig"}A).

An increasing number of studies have revealed the molecular mechanisms responsible for the anti-cancer properties of bufalin. For example, it was found that bufalin treatment resulted in the down-regulation of Wnt/Achaete-scute-like 2 expression in gastric cancer \[[@B31]\], HIF-1α expression via inhibition of the phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B/mammalian target of rapamycin pathway in hepatocellular carcinoma \[[@B50]\], and heat shock protein-27 expression in osteosarcoma cells \[[@B51]\]. In the present study, NSCLC cells treated with bufalin exhibited reduced protein levels of Axl, a TAM RTK known to play important roles in cancer development, chemoresistance, and survival. Bufalin also suppressed the promoter activity of the *Axl* gene, indicating that it down-regulated Axl expression at the transcriptional level ([Figure 2](#F2){ref-type="fig"}B,C). Additionally, bufalin-mediated anti-proliferative activity was attenuated or augmented by *Axl* gene overexpression or knockdown, respectively ([Figures 3](#F3){ref-type="fig"}B--D and [4](#F4){ref-type="fig"}B--D). These results indicate that Axl inhibition by bufalin caused a significant reduction in cell proliferation, highlighting the inverse correlation between the protein expression of Axl and cell proliferation.

Multiple mechanisms are involved in bufalin-induced apoptosis. Bufalin has been shown to inactivate Na+/K+-ATPase in bladder carcinoma cells \[[@B52]\], reduce the expression of human telomerase reverse transcriptase in colorectal, pancreatic, and oral cancer cells \[[@B27],[@B53]\], and down-regulate Mcl-1 expression in NSCLC cells \[[@B29],[@B54]\]. It has also been shown to regulate apoptosis-associated proteins by increasing the expression of the anti-apoptotic protein B-cell lymphoma 2 and decreasing levels of the pro-apoptotic protein Bcl-2-associated X protein, apoptosis-inducing factors, and endonuclease G in tongue cancer cells \[[@B32]\]. Consistent with previous reports, in the present study, bufalin was also found to cause PARP cleavage and phosphorylation of H2AX, confirming the presence of bufalin-induced apoptosis in A549 and H460 cells ([Figure 1](#F1){ref-type="fig"}E). Moreover, we found that bufalin-mediated apoptosis was less prominent in Axl-overexpressing cells than in control cells ([Figure 3](#F3){ref-type="fig"}E), indicating that Axl is a target of bufalin that contributes to its pro-apoptotic activity.

In summary, we verified that bufalin down-regulates the expression of the *Axl* gene at the transcriptional level, in turn inhibiting cell proliferation and inducing apoptosis. Our data suggest that Axl is a valid therapeutic target for bufalin that is critical for its function as an anti-cancer agent in NSCLC cells.
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Bcl-2

:   B-cell lymphoma 2 protein

NSCLC

:   non-small cell lung cancer

PARP

:   poly (ADP-ribose) polymerase

RTK

:   receptor tyrosine kinase

TTBS

:   Tris-buffered saline with 0.05% Tween-20
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